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ABSTRACT  
The purpose of the current study was to evaluate size-tuneable polymeric glycol-
chitosan (GC)-DTPA Gadolinium (Gd) conjugates as MRI contrast agents that can be 
used as a platform for imaging of molecular weight (MW) dependent transport 
processes. GC-DTPA-Gd conjugates of precisely controlled MWs were synthesised 
and evaluated in mice against Gd-DTPA using time series of high-resolution MRI 
images of trunk, head, and xenograft flank tumours. GC-DTPA modification ratio was 
one DTPA per 3.9-5.13 of GC monomers. GC-DTAP-Gd provided overall superior 
contrast compared to Gd-DTPA with the duration of the enhancement depending on 
0:KUIRUN'7KHNLGQH\VVKRZHGHDUO\HQKDQFHPHQWDOVRSDUWLFXODUO\LQWKH
renal pelvis, suggesting renal elimination. Imaging of the head with GC-DTPA-Gd 
allowed detailed anatomical identification of specific blood vessels in articular with 
the high MW CA agent. Sequential, high-resolution, isotropic imaging of established 
A431 xenograft flank tumours with DTPA-Gd and GC-DTPA-Gd demonstrated that 
the initial distribution of the contrast agents was well correlated with blood vessels 
and supply. In contrast, subsequent tissue transport was primarily by diffusion and 
limited by CA molecular weight. The data also highlight the role of heterogeneity in 
CA distribution which was more prominent for the high MW agent. Precise control of 
glycol chitosan (GC) polymer chemistry facilitates synthesis of a family of Gd-based 
MRI contrast agents of tuneable MW but otherwise identical physicochemical 
properties. Such agents allow isotropic high-resolution three dimensional imaging of 
MW dependent transport processes relevant to the clinical and pre-clinical prediction 
of drug transport processes. 
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1. INTRODUCTION 
Around 50% of magnetic resonance imaging (MRI) studies use contrast agents (CA) 
such as Gadolinium (Gd) [1], typically administered in a chelated form to avoid the 
toxicity from free Gd. Most CAs in current clinical use are extracellular fluid agents 
that distribute readily to all tissues and are typically excreted rapidly by renal filtration 
due to their low molecular weight (MW) [2]. However, CAs that remain limited to the 
blood vessels and have an extended plasma half-life are also useful, e.g. for imaging 
studies of longer duration and imaging of the blood vessels in MR angiography. 
Such blood pool CAs would typically require molecular weights large enough to avoid 
extravasation and ready renal filtration, e.g. by binding of Gd-chelates to albumin 
(MW 69 kD, 7-8 nm) [3, 4]. Gadofosveset trisodium (Ablavar ®, Bayer Schering 
Pharma AG) is the first FDA licensed blood pool CA on the market [5]. Blood pool 
agents provide potential advantages for the visualisation of peripheral vascular 
pathology, vascular aspects of CNS or kidney disease, and cancer. For example, the 
progression of solid WXPRXUV UHTXLUHV WKH REOLJDWRU\ DFWLYDWLRQ RI WKH µDQJLRJHQLF 
VZLWFK¶ LH WKH DFWLYDWLRQ RI SDWKZays linked to the development of new blood 
vessels [6]. The developing neovasculature is heterogeneous with atypical 
morphology, and has reduced hydrodynamic and transport functionality. The 
discontinuous endothelial lining allows extravasation of macromolecules and nano-
sized particulates [7] with a consequent increase in interstitial pressure that hampers 
nutrient and drug transport into the tumour parenchyma [8] and has been linked to 
poor prognosis and drug resistance [9]. The effects are thought to be particularly 
important for the transport of higher MW therapeutics such as anti-bodies, 
macromolecules, particulate drug carriers, and gene delivery systems [10]. 
Understanding the impact of MW on transport processes from blood vessels into 
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tissues thus becomes important not only as a diagnostic feature but also as a 
potential predictor and biomarker for the transport of such agents in specific tumours. 
We hypothesised that polymeric MRI CAs of variable MW but identical 
physicochemical properties could be a useful tool for the study of such molecular 
weight dependent transvascular transport processes and chose to test this by 
creating CAs based on glycol chitosan (GC), a versatile biocompatible carbohydrate 
polymer widely used in the development of nanomedicines and nano-diagnostics. 
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2. MATERIALS AND METHODS 
2.1. Synthesis of GC-DTPA 
All reagents were purchased from Sigma-Aldrich, UK. Glycol chitosan (GC) of 
varying molecular weight was obtained by acid degradation [11]. Briefly, GC with a 
degree of polymerisation of 2,500 was degraded (2 hrs, 48 hrs) and recovered by 
filtration, dialysis, and freeze-drying. The depolymerised GC was then reacted with p-
SCN-Bn-DTPA (2-(4-isothiocyanatobenzyl)-diethylenetriamine pentaacetic acid, 
Macrocyclics, USA) in alkaline conditions (24 hrs) and the product obtained after 
dialysis and freeze-drying (Fig. 1). The polymer MW was determined by gel 
permeation chromatography and multi-angle laser light scattering (GPC/ MALLS; 
Dawn EOS, Wyatt Technology) [11]. 1H-NMR and 1H-1H COSY (Bruker AMX 400 
MHZ spectrometer) were performed on GC, p-SCN-Bn-DTPA, and GC-DTPA 
conjugates using deuterated water (D2O). Elemental analysis was carried out on a 
Thermo Finnigan EA1112 instrument (Thermo Scientific). 
 
2.2. Gadolinium Loading 
GC-DTPA conjugate and gadolinium (0.5 mmol) were dissolved in imidazole buffer 
(pH=6.8), mixed and stirred over night to form a precipitate (GC-DTPA-Gd). 
Phosphate buffer (pH=7) was added to the reaction mixture to redissolve GC-DTPA-
Gd and precipitate excess gadolinium. $IWHU*GUHPRYDOE\ ILOWUDWLRQ ȝPDQG
dialysis the final product was obtained by freeze-drying. The Gd loading of the GC-
DTPA polymer was confirmed using isothermal titration calorimetry (ITC), the 
arsenazo assay, and inductively coupled plasma±atomic emission (ICP-AE): For the 
ITC (Microcal VP-ITC, MicroCal Inc., USA) Gd chloride hexahydrate (6.5 mM), DTPA, 
and GC-DTPA (0.2 mM DTPA equivalent) were dissolved (0.1M HCl/NaOH buffer, 
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pH=2) and de-gassed (ThermoVac, MicroCal Inc., USA). Then aliquots of Gd (20-25 
[ȝ/DWPLQZHUHLQMHFWHG into the ITC cell filled with either DTPA or GC-DTPA 
(n=3). Free Gd in solutions of DTPA or GC-DTPA was quantified using the 
absorbance of a Gd-arsenazo complex (653nm) [12]. The Gd content in a range of 
samples of GC-DTPA-GD was measured using ICP-AE (138 UL Trace, Jobin Yvon, 
UK; Vista Pro, Varian Inc.) and Gd standards (0-40mg L-1) at 310nm. 
 
2.2.1. Animal Preparation and Maintenance 
All studies adhered to current national and local regulations and guidelines [13] and 
were approved by the local ethics committee and the UK authorities. Female nude 
mice (CD1-nu, ~20g) were anaesthetized (2-3% isofluorane in 70/30 N2/O2) via a 
facemask. Temperature (maintained at 37 °C using a water jacket), respiration and 
ECG were monitored using a BIOPAC system (Goleta, CA, U.S.A.). Xenograft  
tumours, established by subcutaneous injection of 1x106 A431 epidermoid carcinoma 
cells (ATCC CRL-1555), were used when vascularized (ႇ> 5 mm 10+ days). 
 
2.3. MR Imaging 
All MR imaging was performed on a Bruker Biospin Avance using a 7 T horizontal 
30cm bore magnet. In all cases mice were introduced into the bore of the magnetic 
using a plastic cradle. Trunk imaging was carried out with a 35mm RF resonator coil 
(gradient maximum 200 mT m-1), other images used a Bruker micro-imaging gradient 
insert (BG-6, 60 mm ID, 100 A amplifier; gradient maximum 1000 mT m-1, rise time of 
ȝVRUDGHGLFDWHGRSWLPL]HGWXPRXUVROHQRLG5)PLFUR- coil, built into the animal 
cradle [14]. The trunk with a focus on the kidneys was imaged using a four slice multi 
slice multi echo (MSME) 2D sequence with in-plane isotropic YR[HOVîȝP2, 
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slice thickness of 2 mm, in-plane FoV 60 × 34 mm. The sequence (TE=10.5 ms, 
TR=75 ms, a flip angle of 90° with a 180° re-focusing pulse and four averages) 
required a total scan time of 1 min 7 sec. The brain was imaged using a 3D FLASH 
sequence with isotURSLFYR[HOVîîȝP3 and a field of view 20 × 16 × 16 
mm3. This sequence used an echo time of 3.7 ms, a repetition time of 20 ms, a flip 
angle of 30°, and one average. The data was visualised using maximum intensity 
projections (MIPs) in three directions before and after (3 min 20 sec) administration. 
MIPs technique is an effective way to visualise 3D data sets, which involves 
constructing a 2D (x,y) image in which each pixel contains the maximum value at that 
(x,y) location in the third dimension (z). A 3D FLASH sequence was also used to 
image tumours using isotropic ȝP3 voxels in a field of view of 8 x 8 x 8 mm3 with 
an echo time of 3.5 ms, a repetition time of 25.0 ms, a flip angle of 30°, and either 
two or four averages with total scan times of 5 min 20 sec and 10 min 40 sec, 
respectively. Tumour angiography studies used a multi-slice 2D time of flight (TOF) 
gradient echo sequence sliced perpendicular to the axis of the coil or sagittal in 
anatomical terms with isotropic ȝP3 voxels in-plane resolution and 60 sequential 
VOLFHVRIȝPWKLFNQHVV7KHHFKRWLPe used was 5 ms and the recovery time was 
40 ms with 8 averages. Scans of trunk, head and tumour were performed on different 
animals. In addition, MRI studies using GC-DTPA-Gadolinium conjugates and Gd-
DTPA were carried out following the injection of the contrast agents to the same 
animal, separated by an adequate washout period. Raw data was exported as free 
induction decay (FID) file and then processed using Interactive 
Data Language (IDL, RSI, Boulder, Colorado, U.S.A.) routines. 
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3. RESULTS 
3.1. GC-DTPA Synthesis 
The acid degradation of glycol chitosan reduces the polymer MW in a nonlinear 
manner following a first order reaction with a first order rate constant of ±1.35 
0Q  Hí1.346t + 7041, r2=0.99) [15]. The molecular weight of the resultant 
polymer can be selected based on the choice of reaction conditions, in particular 
reaction time and temperature [15]. The reaction produces polymers of low 
polydispersity (Mw/Mn ~1.07-1.3) with a yield inversely proportional to the 
degradation time (49-75%, low MW polymer is lost in dialysis) and a weight average 
MW of 37.8±1.4 kDa (GC40), 16.6±1.6 kDa (GC16) and 12.3±1.9 kDa (GC12), 
respectively. The yield of the GC-DTPA conjugation step was 61-86% with the 
freeze-dried product obtained as an off-white/yellow cotton like product. The NMR 
analysis confirms the product and very low N-acetylation levels (< 0.05 mol% at 2.0 
ppm, Fig. 1). Signals from the polymer and DTPA overlap but the benzene group at 
į-7.5 indicates the presence of the benzyl isothiocyanate moiety of p-SCN-Bn-
DTPA. Furthermore, a new peak for the GC anomeric proton becomes detectable 
at 4.4ppm, presumably as a result of conformational changes of the polymer. The 
conjugation level of GC-DTPA was measured using elemental analysis, an arsenazo 
III assay, and ITC. Based on the elemental nitrogen and sulphur the number of GC 
monomers per DTPA pendant group was calculated as 5.15 (GC40-DTPA), 3.96 
(GC16-DTPA), and 4.89 (GC12-DTPA), respectively (Table 1). Gd3+ ions bind to 
arsenazo III to form the colorimetrically detectable complex (log K = 15.85 [12]) only 
once DTPA has been saturated with Gd to form the DTPA-Gd complex (log K = 
22.46 [16]). The colorimetric Gd arsenazo III complex thus allows measurement of 
free and GC-DTPA chelated Gd from which the level of conjugation (GC moles/DTPA 
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moles) was determined to be 4.83 (GC40-DTPA), 3.94 (GC16-DTPA), and 5.37 
(GC12-DTPA), respectively (Table 1). ITC was used to measure heat enthalpy of the 
GC-DTPA/Gd3+ interactions for GC16-DTPA and to determine the conjugation level 
by comparison with free DTPA and Gd (Fig. 2). At the acidic pH used in this 
experiment (pH=2), the carboxylic groups of DTPA are protonated (un-ionised) and 
interactions with Gd3+ occur at a slower rate. Initial Gd injections produce large peaks 
resulting from the binding of Gd3+ to DTPA. As the concentration of free DTPA 
reduces the heat reduces to the heat of dilution represented by the small peaks at 
the end of the curve. The stoichiometry of binding (GC16-DTPA:Gd) was used to 
calculate the GC:DTPA molar ratio which was of 3.79±0.05. The yield for the off-
white to yellow freeze-dried product was 217 mg (GC40-DTPA-Gd) and 120mg 
(GC16-DTPA-Gd), respectively. The average ratio (ICPAES) of Gd per mg of GC-
DTPA-Gd was 0.079±0.003 mg for GC40-DTPA-Gd, 0.100±0.005 mg for GC16-
DTPA-Gd, and 0.073±0.005 mg for GC12-DTPA-Gd.  
 
3.2. Magnetic Resonance Imaging Results 
The initial biodistribution was imaged over 29 min post the intravenous administration 
of GC16-DTPA-Gd (0.1 mmole Gd kg-1). The MR imaging of the trunk showed very 
clearly highlighted kidneys when compared to the pre-administration image (Fig. 3). 
Immediately after injection detailed imaging shows GC40-DTPA-Gd and GC12-
DTPA-Gd in the kidneys with rapid passage to renal pelvis and then ureter. Although 
the level of contrast decreased over time, the kidneys remained highlighted.  
Magnevist, when administered at the same dose of Gd, yielded only low level of 
dynamic contrast enhancement (Fig. 3). Renal enhancement has been suggested as 
being indicative of contrast agent removal from the blood and elimination by the 
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kidneys [17]. The higher molecular weight GC40-DTPA-Gd continued to be present 
in WKH NLGQH\ IRU D ORQJHU SHULRG RI WLPH  PLQ VXJJHVWLQJ D longer plasma 
residence time consistent with a larger polymer MW. The data suggest these CAs 
are filtered in a MW dependent fashion by the kidneys and eliminated in the urine. 
When a very short TR is used (as in this study), the effect of the contrast agent on T1 
relaxation time diminishes unless the agent exhibits a high relaxivity or is present at a 
high concentration at the site of interest, or both. This explains the higher contrast in 
GC-DTPA-Gd images resulting from the increased relaxivity of the polymer-based 
contrast agents when compared to Magnevist. The imaging properties of Magnevist, 
GC40-DTPA-Gd, and GC12-DTPA-Gd were compared further by imaging the 
cranium (Fig. 4). In contrast to Magenvist, GC40-DTPA-Gd remains confined to the 
blood pool giving a much clearer enhancement of the brain vasculature while GC12-
DTPA-Gd shows an intermediate effect. This blood pool selectivity dramatically 
changes the structures and detail that can be visualised from the volume data as 
shown by Maximum Intensity Projections (MIPs) (Fig. 4). These visualise regions with 
a level of enhancement greater than 20% based on the differential between 
preinjection and post-injection contrast (t=3 min 20 sec). The CAs show a distinct 
distribution with signal time profiles dependent on anatomical location. Regions of 
interest (ROI) representing brain parenchyma, blood vessels, and surrounding tissue 
were identified and signal intensities compared over time (Fig. 5). All CAs show a 
sharp initial enhancement in the major blood vessel. While both Magnevist and 
GC12- DTPA-Gd show a brief peak, the higher MW GC40-DTPAGd shows a 
sustained enhancement suggesting a prolonged plasma half-life compared to the 
lower MW agents. However, the signal decay at one hour suggests signal intensities 
would reach pre-contrast levels within two hours. Both polymeric CAs GC40-DTPA-
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Gd and GC12-DTPA-Gd do not enhance contrast in the brain parenchyma or the 
surrounding connective tissue (Fig. 5 b and c). Conversely the connective tissue 
region shows the greatest enhancement and longest time to peak when imaged with 
Magnevist, suggestive of a diffusion dependent accumulation (Fig. 5a). The vascular 
contrast enhancement using the GC40-DTPA-Gd is sufficient to allow anatomical 
identification of specific larger blood vessels using regional maximum intensity 
projections. Based on the differential contrast of the high and low MW polymers 
these CAs were applied to the investigation of molecular weight dependent transport 
processes in solid tumours. Transport limitations of individual tumours were 
visualised by sequential imaging of low and high MW CAs administered to the same 
animal and same tumour, separated by a washout period (Fig. 6). For both agents 
initial delivery to the tumour was correlated with blood supply. As would be expected 
the lower molecular weight material exhibited greater diffusion and consequently 
covered a larger area of the tumour. A volume projection highlights the overall 
disparity in tumour coverage of the two agents. The heterogeneity of distribution 
relates to identifiable anatomical structural detail but is also linked to the difference in 
CA molecular weight. 
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4. DISCUSSION 
Molecular weight is one of the key factors determining biological behaviour of 
macromolecules in terms of biodistribution, and vascular and tissue transport. Here 
we explore the use of biocompatible polymers with defined and tailored molecular 
weights as the basis of a family of MRI CAs to explore these processes by MRI. Such 
CAs, having the same physical chemistry but different molecular weights, could be 
adapted to serve preferentially as blood pool CAs or to study macromolecular 
transport processes. The potential for polymer- based CAs with enhanced blood 
residence time has previously been explored. When poly-L-lysine-GTPA of 
increasing MW were explored as potential blood pool agents it has previously been 
shown that plasma half-life is increased and renal clearance reduced with increasing 
MW [18]. However, agents such as carboxy methyl dextran±GTPA have limited utility 
in exploring MW dependent processes because of their broad MW distribution (10-
163 kD) [19]. On the other hand, CAs with a defined molecular structure, such as 
dendrimers, possess monodisperse MWs but do not easily allow continuous tuning of 
polymer molecular weight [20]. Using CAs with shared chemical structure and 
physical chemistry but different MW minimises the risk of variable interactions with 
biological macromolecules. Such binding would potentially lead to changes in 
relaxivity thus complicating direct comparisons. MW is not only a key determinant of 
a CAs potential utility as a blood pool agent but can also be used to assess 
pathological transport processes. Once tumours are able to induce the growth of new 
vasculature (angiogenic switch) they may proliferate and metastasise. The 
GHYHORSLQJµOHDN\¶ vasculature allows extravasation of macromolecules that leads to 
an increase in interstitial pressure leading to diffusion (or perfusion) limited transport 
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into the tumour parenchyma which affects low MW drugs [21] but even more higher 
MW therapeutics such as anti-bodies, macromolecules particulate drug carriers, 
gene delivery systems [10], and which has been linked to poor prognosis and drug 
resistance [9]. MRI has been applied to understand and quantify such transport 
processes, in particular by applying DCE-MRI and associated mathematical 
derivation of parameters such as transfer co-efficient, vascular volume fraction and 
measures of permeability and perfusion, typically applying models based on the 
unidirectional transfer of contrast material between compartments such as the Tofts 
two compartment model [22] and the three-compartment model [23]. The current 
study analyses the relationships between blood supply and contrast agent delivery 
directly and in high resolution. 
The data emphasises the important role of underlying anatomical structures and local 
tissue heterogeneity in determining the detailed spatiotemporal distribution of 
molecules of different molecular weight. The concept of using MRI contrast agents as 
surrogates for drugs to investigate tumour delivery and transport issues itself is not 
new. Both low molecular weight contrast materials [24] and macromolecular contrast 
materials [25] have been used to predict the delivery and transport of drugs of a 
similar molecular weight. In both cases the delivery of the drug, confirmed by 
histology, proved to be well correlated with the prediction by MRI. 
Furthermore, studies have been performed in which contrast agents with different 
molecular weights have been serially administrated to the same tumour in order to 
optimise modelling procedures [26, 27]. The studies reported here would appear to 
be the first time to show that these two concepts (the use of contrast agents as drug 
surrogates and the serial administration of contrast agents with different molecular 
weights) could be brought together. Here we synthesised and characterised GC-
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DTPA-Gd3+ as a biocompatible macromolecular contrast agent for which the 
molecular weight can be tuned precisely for various imaging purposes. We 
demonstrate its utility as a blood pool agent by detailed imaging of mouse brain 
vascular architecture, show that filtration via the kidney provides early and sustained 
contrast enhancement in the kidney, and provide evidence that GC-DTPA-Gd of high 
and low MW can be used to characterise molecular weight dependent transport in 
murine xenograft tumours with a high spatial and temporal resolution. The imaging 
also shows that the diffusion (or perfusion) distances for higher molecular weight 
materials were lower than for low molecular weight materials. Data from doxorubicin 
treated breast cancers demonstrate that heterogeneity in drug distribution at the 
histological level can persist for many hours [21] but work in experimental tumours 
suggests that vascular supply can also change rapidly over time [28]. Our data 
highlights the potential role of such transport differences for the heterogeneity of drug 
exposure and subsequent resistance in tumours, in particular with respect to drug 
MW. 
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CONCLUSION 
Precise control of glycol chitosan polymer chemistry facilitates synthesis of Gd-based 
MRI contrast agents with defined molecular weights which allow isotropic high 
resolution three-dimensional imaging of the heterogeneity of molecular weight 
dependent transport processes, in particular in tumours, in order to understand and 
potentially predict effects on therapy. Studies of this type using a series of well 
calibrated CAs, differing only by MW, could potentially provide a surrogate biomarker 
for accessibility and transport of drug treatments in tumours. In drug development 
terms this may also help in the selection of a suitable tumour models to test new high 
MW treatments. 
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FIGURE LEGENDS 
 
Table 1. Characteristics of GC-DTPA conjugates and level of conjugation, 
represented by number of GC monomers per DTPA pendant group, measured using 
elemental analysis, arsenazo III assay, and ITC. 
 
Fig. (1). Structure, reaction scheme, and annotated 1H-NMR spectra of GC-DTPA in 
D2O indicating the presence of the benzylisothiocyanate moiety of p-SCN-Bn-DTPA 
at 7.3-7.5. 
 
Fig. (2). Determination of the conjugation level of GC-DTPA/Gd3+ based on the 
measurement of heat enthalpy. Injection of Gd3+ (6.5 mM) into a buffered aqueous 
solution of GC16-DTPA (0.2 mM based on p-SCN-Bn-DTPA, 25 oC and pH = 2) 
yields a titration curve showing heat flow against amount of injected Gd3+(top) and of 
enthalpy versus molar ratio (bottom). 
 
Fig. (3). Time course of trunk MR of mice imaged over 28 min and injected with 
Magnevist (top panel) and GC40-DTPA-G at 0.1 mmole Gd.kg-1 (bottom panel). The 
polymer CAs shows an enhanced level of contrast over a significantly prolonged 
duration compared to Magnevist as well as early enhancement of the kidney 
parenchyma and renal pelvis. 
 
Fig. (4). MR imaging of a mouse head after administration of (a) Magnevist, (b) C12-
DTPA-Gd, and (c) GC40-DTPA-Gd. Left panel: Maximum intensity projections of the 
cranium in the coronal, sagittal, and transverse planes prior and 3 mins 20 sec after 
administration of CAs. Middle panel: Volume projections showing areas of greater 
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than 20% enhancement demonstrate the different levels of vascular retention of the 
agents. Right panel: Maximum intensity projections of murine brain imaged using 
GC40-DTPA-Gd allow visualisation of cranial vasculature in sufficient to allow 
anatomical identification of blood vessels (1-Superior sagittal sinus; 2-Lateral 
superior cerebellar artery; 3-Common carotid artery; 4-Posterior cerebral artery). 
 
Fig. (5). MR images and time dependent contrast intensity profiles of the mouse 
cranium imaged using (a) Magnevist, (b) GC12-DTPA-Gd, and (c) GC40-DTPA-Gd. 
A number of specific anatomical regions of interest (ROI) were identified (red = brain 
parenchyma, blue = brain blood supply, green & turquoise = tissue surrounding the 
brain). The contrast intensity in those structures was then extracted from the 4D data 
stack and plotted over time yielding intensity-time curves.  
 
Fig. (6). Comparison of molecular weight dependent contrast enhancement in a 
tumour. A431 epidermoid carcinoma flank tumour in a mouse imaged over a period 
of 20 min after intravenous administration of first Magnevist followed by GC40-DTPA-
Gd (top panel). Changes in the distribution between low (Magnevist) and high MW 
CA (GC40-DTPA-Gd) between 0 to 10 min and 10 to 20 min are visualised, 
respectively (bottom panel, left). High and low MW agent distribution 20 min after 
injection in the same tumour is visualised as a volume projection of CA distribution 
(bottom right panel). 
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